



#### VRL/SEC/EXCHANGE

01.09.2017

National Stock Exchange of India Ltd.

5<sup>th</sup> Floor, Exchange Plaza Bandra (E), Mumbai- 400 051 Script Code: VENUSREM Dept. of Corporate Services
The Stock Exchange, Mumbai
25<sup>th</sup> Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai

Sub: Submission of Unaudited Financial results for the quarter ended on 30.06.2017

Script Code: 526953

Dear Sir/Madam,

Please find enclosed herewith copy of Unaudited Financial Results for the quarter ended on 30.06.2017 along with Limited Review Report which were taken on record by the Board of Directors at its meeting held on 01.09.2017.

Disclosure regarding qualification of audit report also enclosed herewith.

Kindly acknowledge the receipt

Thanking you.

Yours faithfully, for VENUS REMEDIES LIMITED

(Company Secretary)

#### **VENUS REMEDIES LIMITED**

51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India

Regd. Office:

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra, Chandigarh (U.T.) 160101, India

#### Unit-I:

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India Tel.: +91-172-3933094, 3933090, 2565577, Fax: +91-172-2565566

Unit-II:

II:





# STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30th JUNE, 2017

( Rs. In millions)

			Rs. In millions)
S.	PARTICULARS	30-06-2017	30-06-2016
No.		Unaudited	Unaudited
1	Income		
	(a) Revenue from Operations	782.26	1031.45
	(b) Other Income	1.26	1.24
	Total Income	783.52	1,032.69
2	Expenses	411.52	662.17
	(a) Cost of Material Consumed	1000	-18.19
	(b) Changes in Inventories of finished goods, work -in -progress Stock in Trade	10.05	
	(c) Employee benefits expense	65.15	59.08
	(d) Finance Cost	80.52	69.55
	(e) Depreciation & amortization expense	101.74	98.79
	(f) Other expenses	106.07	149.10
	Total Expense	775.05	1,020.50
3	Profit before exceptional items and taxes ( 1-2 )	8.47	12.19
4	Exceptional items	N 1 1 / 3	5/
5	Profit before tax (3 +/- 4)	8.47	12.19
6	Income Tax Expense		(0.17
7	Profit for the period (5+/-6)	8.47	12.36
8	Other Comprehensive Income		
Α	(I) Items that will not be classified to profit & loss	1 1 1 1	(0.28
В	(II) Items that will be classified to profit & loss	- N	
	Total other comprehensive Income Net of Income Tax		(0.28
9	Total comprehensive Income for the period (7+/-8)	8.47	12.08
10	Paid up equity share capital	123.42	
	( Face Value of Equity Shares)	10	11
11	Earning per share ( of Rs. 10/- each ) (Not annulized)		
	(a) Basic	0.69	
	(b) Diluted	0.69	1.0

## **VENUS REMEDIES LIMITED**

Corporate Office : 51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India

Regd. Office:

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,

Unit-I: 51-52, Industrial Area, Phase-I, Panchk (14) 17, 134113, India Tel.: +91-172-3933094, 3933090, 25655

Unit-II :

Hill Top Industrial Estate Tharmairi EPIP Phase-I (Extn.)





Notes to the financial results:-

- 1. The above standalone unaudited financial results of the company have been reviewed by the Audit Committee and approved by the Board of directors at their respective meetings held on 01-09-2017. The statutory auditors of the company have conducted a Limited Review of the above standalone unaudited financial results for the quarter ended June 30- 2017.
- 2. This statement has been prepared in accordance with the companies (Indian Accounting Standards) rules, 2015 (IND-AS) prescribed under section 133 of the company act 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1<sup>st</sup> 2017, the company has for the 1<sup>st</sup> time adopted India Accounting standards (Ind AS) with a transition date of 1<sup>st</sup> April 2016.
- 3. The standalone financial results and other financial information for the quarter ended June 30, 2016 have not been audited or reviewed by the statutory auditor. However the management has exercised necessary due diligence to ensure that the standalone unaudited financial results provide a true and fair view of the Company's affairs.
- 4. The statement does not include IND AS compliant results for the preceding quarter and previous year ended 31st March 2017 as the same is not mandatory as per SEBI circular dated 5th July 2016
- 5. Reconciliation of Net Profit / loss for the quarter ended June 30, 2016 under India GAAP (previous GAAP) and Ind AS is as under:

Particulars	Quarter ended 30-06-2016 Unaudited (Rs. In Millions)	
Net Profit / (Loss) for the quarter as per Previous GAAP	11.84	
Add / (Less) : Adjustment for GAAP Difference	ALSO IN	
Changes in Employee benefits.	0.35	
Change in Deferred Tax	0.17	
Net Profit / (Loss) for the quarter as per Ind AS  Other comprehensive income , net of income tax	12.36	
Total Comprehensive Income for the period	(0.28)	
	12.08	

## **VENUS REMEDIES LIMITED**

Corporate Office:

51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India

Regd. Office:

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,

Unit-I:

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India Tel.: +91-172-3933094, 3933090, 2565577, Fax: +91-172-2565566

Unit-II :

Hill Top Industrial Estate .lharmairi EPIP Phase-I (Eytn.)





- 6. Figures for the previous period have been regrouped / reclassified wherever necessary to conform to the current period classification.
- 7. Company has only reportable segment namely "Pharmaceuticals"

For and on behalf of Board of Directors For VENUS REMEDIES LIMITED

Date: 01.09.2017

Pawan Chaudhary (Chairman & Managing Director)

DIN: 00435503

## **VENUS REMEDIES LIMITED**

Corporate Office:

51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India

Regd. Office:

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra, Chandigarh (U.T.) 160101 India

**Unit-I :** 51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmairi EPIP, Phase-I. (Extn.).



# **Prem Garg & Associates**

CHARTERED ACCOUNTANTS

S.C.O. 2461, SECTOR 22-C, CHANDIGARH Service Tax No. : AADFP9547JST001

PAN No.: AADFP9547J

Phone: 0172-2774934, Fax: 4652400 Mobile: 09872420001, 9417012475

E-mail: premgarg@yahoo.com

The Board of Directors , Venus Remedies Limited , 51-52 , Industrial area , Phase – I, Panchkula .

We have reviewed the accompanying statement of unaudited financial results of Venus Remedies limited for the period ended on 30/06/2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable India specified under section 133 of companies act ,2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for Prem Garg & Associates Chartered Accountants

( Dinesh Kame buntant

Partner

Place: Chandigarh Date: 01.09.2017